Congress funds cerebral palsy research for first time in federal program
H.R. 2178 — Cerebral Palsy Research Program Authorization Act of 2025 · Filed by Steve Cohen (D-TN) · 8 cosponsors · Introduced Mar 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the Secretary of Health and Human Services, through the CDC, to conduct and fund research on cerebral palsy—a lifelong motor disorder affecting over 1 million Americans. The program would study diagnosis, treatment, prevention, surveillance, and health-care costs, with an authorized budget of $5 million per year for 2026–2031. The bill creates no new restrictions or liabilities; it simply establishes a federal research initiative.
Why we flagged it
The bill's sole operative mechanism is authorizing and funding federal research into cerebral palsy diagnosis, treatment, and prevention through the CDC. It contains no deregulation, liability shields, tax carve-outs, or private-sector giveaways—only a straightforward public-health research mandate.
What the text implies
- The $5M annual authorization is modest relative to the $13.5B+ lifetime cost burden cited in findings; actual appropriations may fall short of research needs.
- The bill grants the CDC Director broad discretion to determine 'appropriate' research areas (subsection 3), which could allow scope creep or deprioritization depending on agency leadership.
The full analysis lists 3 implications of this text.
Who stands to gain
research institutions and universities (grant recipients); CDC contractors and research partners